Pfizer to Supply Up to Six Million Paxlovid Treatment Courses to Global Fund
Pfizer has promised to supply up to six million treatment courses of its Paxlovid (nirmatrelvir, ritonavir) to the Global Fund for treatment of COVID-19 infections.
The oral drugs will be made available to low- and middle-income countries at a not-for-profit price while upper-middle-income countries will pay tiered pricing, the company said.
Paxlovid is currently FDA-authorized for treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg.
Contractual details of the Global Fund agreement were not disclosed.